Hypermethylation of genes for diagnosis and risk stratification of prostate cancer

Cancer Investigation

Volumn 27, Issue 5, 2009, Pages 549-560

  Vanaja, Donkena Krishna ^a   Ehrich, Mathias ^b   Van Den Boom, Dirk ^b   Cheville, John C ^a   Karnes, R Jeffrey ^a   Tindall, Donald J ^a   Cantor, Charles R ^b   Young, Charles Y F ^a,c  

^a MAYO CLINIC   (United States)

^b SEQUENOM INC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

CpG site methylation; Mass spectrometry assay; Molecular markers; Prostate cancer; Recurrence prediction

Indexed keywords

EMBRYONAL FYN ASSOCIATED SUBSTRATE PROTEIN; ESOPHAGEAL CANCER RELATED GENE 4 PROTEIN; FILAMIN; FILAMIN C; GLUTATHIONE TRANSFERASE P1; LIM PROTEIN; PAIRED LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 2; PDZ AND LIM DOMAIN 4 PROTEIN; PDZ PROTEIN; POTASSIUM LARGE CONDUCTANCE CALCIUM ACTIVATED CHANNEL SUBFAMILY M ALPHA MEMBER 1 PROTEIN; PROTEIN; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; UNCLASSIFIED DRUG; DNA; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; CPG ISLAND; GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN METHYLATION; RISK ASSESSMENT; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RISK FACTOR; TUMOR RECURRENCE;

CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 67449097913     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802620794     Document Type: Article

References (58)

1. Nielsen, M.E.; Partin, A.W. The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev Urol 2007, 9(2), 57-62.
2. Nguyen, P.L.; Chen, M.H.; Catalona, W.J.; Moul, J.W.; Sun, L.; D'Amico, A.V. Predicting prostate cancer mortality Among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2008.
3. D'Amico, A.V.; Hui-Chen, M.; Renshaw, A.A.; Sussman, B.; Roehl, K.A.; Catalona, W.J. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 2006, 176(6 Pt 2), S11-15.
4. Thompson, R.H.; Blute, M.L.; Slezak, J.M.; Bergstralh, E.J.; Leibovich, B.C. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol 2007, 178(2), 459-463; discussion 463.
5. Eastham, J.A.; Scardino, P.T.; Kattan, M.W. Predicting an optimal outcome after radical prostatectomy: the Trifecta nomogram. J Urol 2008, 179(6), 2207-2210; discussion 2210-12201
6. Roberts, W.W.; Bergstralh, E.J.; Blute, M.L.; Slezak, J.M.; Carducci, M.; Han, M.; Epstein, J.I.; Eisenberger, M.A.; Walsh, P.C.; Partin, A.W. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001, 57(6), 1033-1037.
7. Stephenson, A.J.; Scardino, P.T.; Eastham, J.A.; Bianco, F.J., Jr.; Dotan, Z.A.; Fearn, P.A.; Kattan, M.W. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006, 98(10), 715-717.
8. D'Amico, A.V.; Chen, M.H.; Roehl, K.A.; Catalona, W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351(2), 125-135.
9. Hanks, G.E.; Hanlon, A.L.; Lee, W.R.; Slivjak, A.; Schultheiss, T.E. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996, 34(3), 549-553.
10. Sengupta, S.; Myers, R.P.; Slezak, J.M.; Bergstralh, E.J.; Zincke, H.; Blute, M.L. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005, 174(6), 2191-2196.
11. Thompson, I.M.; Pauler, D.K.; Goodman, P.J.; Tangen, C.M.; Lucia, M.S.; Parnes, H.L.; Minasian, L.M.; Ford, L.G.; Lippman, S.M.; Crawford, E.D.; Crowley, J.J.; Coltman, C.A., Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004, 350(22), 2239-2246.
12. Blute, M.L.; Bergstralh, E.J.; Iocca, A.; Scherer, B.; Zincke, H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001, 165(1), 119-125.
13. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128(4), 683-692.
14. Laird, P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3(4), 253-266.
15. Ting, A.H.; McGarvey, K.M.; Baylin, S.B. The cancer epigenome - components and functional correlates. Genes Dev 2006, 20(23), 3215-3231.
16. Brueckner, B.; Kuck, D.; Lyko, F. DNA methyltransferase inhibitors for cancer therapy. Cancer J 2007, 13(1), 17-22.
17. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429(6990), 457-463. (Pubitemid 38715140)
18. Moggs, J.G.; Goodman, J.I.; Trosko, J.E.; Roberts, R.A. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol 2004, 196(3), 422-430. (Pubitemid 38496465)
19. Yoo, C.B.; Jones, P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5(1), 37-50.
20. Enokida, H.; Shiina, H.; Urakami, S.; Igawa, M.; Ogishima, T.; Li, L.C.; Kawahara, M.; Nakagawa, M.; Kane, C.J.; Carroll, P.R.; Dahiya, R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005, 11(18), 6582-6588. (Pubitemid 41338998)
21. Vanaja, D.K.; Ballman, K.V.; Morlan, B.W.; Cheville, J.C.; Neumann, R.M.; Lieber, M.M.; Tindall, D.J.; Young, C.Y. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res 2006, 12(4), 1128-1136. (Pubitemid 43342500)
22. Vanaja, D.K.; Cheville, J.C.; Iturria, S.J.; Young, C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003, 63(14), 3877-3882.
23. Ehrich, M.; Field, J.K.; Liloglou, T.; Xinarianos, G.; Oeth, P.; Nelson, M.R.; Cantor, C.R.; van den Boom, D. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 2006, 66(22), 10911-10918. (Pubitemid 44876989)
24. Freedland, S.J.; Aronson, W.J.; Presti, J.C., Jr.; Amling, C.L.; Terris, M.K.; Trock, B.; Kane, C.J. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer 2004, 100(8), 1633-1638.
25. Stephenson, A.J.; Kattan, M.W.; Eastham, J.A.; Dotan, Z.A.; Bianco, F.J., Jr.; Lilja, H.; Scardino, P.T. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006, 24(24), 3973-3978.
26. Kupelian, P.A.; Elshaikh, M.; Reddy, C.A.; Zippe, C.; Klein, E.A. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002, 20(16), 3376-3385.
27. Freedland, S.J.; Sutter, M.E.; Dorey, F.; Aronson, W.J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003, 61(2), 365-369. (Pubitemid 36206534)
28. Boorjian, S.A.; Karnes, R.J.; Rangel, L.J.; Bergstralh, E.J.; Blute, M.L. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008, 179(4), 1354-1360; discussion 1360-11351
29. Takai, D.; Jones, P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002, 99(6), 3740-3745. (Pubitemid 34252176)
30. Gardiner-Garden, M.; Frommer, M. CpG islands in vertebrate genomes. J Mol Biol 1987, 196(2), 261-282.
31. Goessl, C.; Krause, H.; Muller, M.; Heicappell, R.; Schrader, M.; Sachsinger, J.; Miller, K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000, 60(21), 5941-5945. (Pubitemid 30839618)
32. Hanson, J.A.; Gillespie, J.W.; Grover, A.; Tangrea, M.A.; Chuaqui, R.F.; Emmert-Buck, M.R.; Tangrea, J.A.; Libutti, S.K.; Linehan, W.M.; Woodson, K.G. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006, 98(4), 255-261.
33. Hampton, T. New markers may help predict prostate cancer relapse risk. JAMA 2006, 295(19), 2234-2238. (Pubitemid 43736562)
34. Li, L.C.; Dahiya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18(11), 1427-1431.
35. Jornsten, R.; Yu, B. Simultaneous gene clustering and subset selection for sample classification via MDL. Bioinformatics 2003, 19(9), 1100-1109. (Pubitemid 36790011)
36. Hess, K.R.; Anderson, K.; Symmans, W.F.; Valero, V.; Ibrahim, N.; Mejia, J.A.; Booser, D.; Theriault, R.L.; Buzdar, A.U.; Dempsey, P.J.; Rouzier, R.; Sneige, N.; Ross, J.S.; Vidaurre, T.; Gomez, H.L.; Hortobagyi, G.N.; Pusztai, L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24(26), 4236-4244. (Pubitemid 46630780)
37. Tibshirani, R.; Hastie, T.; Narasimhan, B.; Chu, G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002, 99(10), 6567-6572. (Pubitemid 34526173)
38. Yu, Y.P.; Landsittel, D.; Jing, L.; Nelson, J.; Ren, B.; Liu, L.; McDonald, C.; Thomas, R.; Dhir, R.; Finkelstein, S.; Michalopoulos, G.; Becich, M.; Luo, J.H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004, 22(14), 2790-2799.
39. Singh, D.; Febbo, P.G.; Ross, K.; Jackson, D.G.; Manola, J.; Ladd, C.; Tamayo, P.; Renshaw, A.A.; D'Amico, A.V.; Richie, J.P.; Lander, E.S.; Loda, M.; Kantoff, P.W.; Golub, T.R.; Sellers, W.R. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1(2), 203-209. (Pubitemid 41039166)
40. Lapointe, J.; Li, C.; Higgins, J.P.; van de Rijn, M.; Bair, E.; Montgomery, K.; Ferrari, M.; Egevad, L.; Rayford, W.; Bergerheim, U.; Ekman, P.; DeMarzo, A.M.; Tibshirani, R.; Botstein, D.; Brown, P.O.; Brooks, J.D.; Pollack, J.R. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004, 101(3), 811-816. (Pubitemid 38121040)
41. Dhanasekaran, S.M.; Barrette, T.R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K.J.; Rubin, M.A.; Chinnaiyan, A.M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412(6849), 822-826. (Pubitemid 32801464)
42. Bastian, P.J.; Palapattu, G.S.; Lin, X.; Yegnasubramanian, S.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005, 11(11), 4037-4043.
43. Yegnasubramanian, S.; Kowalski, J.; Gonzalgo, M.L.; Zahurak, M.; Piantadosi, S.; Walsh, P.C.; Bova, G.S.; De Marzo, A.M.; Isaacs, W.B.; Nelson, W.G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004, 64(6), 1975-1986. (Pubitemid 38339443)
44. Li, L.C.; Carroll, P.R.; Dahiya, R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005, 97(2), 103-115. (Pubitemid 40277090)
45. Lotan, R.; Lotan, Y. Retinoic acid receptor beta2 hypermethylation: implications for prostate cancer detection, prevention, and therapy. Clin Cancer Res 2004, 10(12 Pt 1), 3935-3936. (Pubitemid 38812465)
46. Lin, X.; Tascilar, M.; Lee, W.H.; Vles, W.J.; Lee, B.H.; Veeraswamy, R.; Asgari, K.; Freije, D.; van Rees, B.; Gage, W.R.; Bova, G.S.; Isaacs, W.B.; Brooks, J.D.; DeWeese, T.L.; De Marzo, A.M.; Nelson, W.G. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001, 159(5), 1815-1826. (Pubitemid 33062524)
47. Henrique, R.; Jeronimo, C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004, 46(5), 660-669; discussion 669. (Pubitemid 39345744)
48. Bernardini, S.; Miano, R.; Iori, R.; Finazzi-Agro, E.; Palmieri, G.; Ballerini, S.; Angeloni, C.; Orlandi, A.; Bellincampi, L.; Cortese, C.; Federici, G. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker? Clin Chim Acta 2004, 350(1-2), 181-188.
49. Bastian, P.J.; Nakayama, M.; De Marzo, A.M.; Nelson, W.G. [GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer]. Urologe A 2004, 43(5), 573-579.
50. Rosenbaum, E.; Hoque, M.O.; Cohen, Y.; Zahurak, M.; Eisenberger, M.A.; Epstein, J.I.; Partin, A.W.; Sidransky, D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005, 11(23), 8321-8325. (Pubitemid 41746943)
51. Jeronimo, C.; Henrique, R.; Hoque, M.O.; Mambo, E.; Ribeiro, F.R.; Varzim, G.; Oliveira, J.; Teixeira, M.R.; Lopes, C.; Sidransky, D. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004, 10(24), 8472-8478. (Pubitemid 40053412)
52. Kang, G.H.; Lee, S.; Lee, H.J.; Hwang, K.S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004, 202(2), 233-240.
53. Bastian, P.J.; Ellinger, J.; Heukamp, L.C.; Kahl, P.; Muller, S.C.; von Rucker, A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007, 51(3), 665-674. (Pubitemid 46097267)
54. Varambally, S.; Yu, J.; Laxman, B.; Rhodes, D.R.; Mehra, R.; Tomlins, S.A.; Shah, R.B.; Chandran, U.; Monzon, F.A.; Becich, M.J.; Wei, J.T.; Pienta, K.J.; Ghosh, D.; Rubin, M.A.; Chinnaiyan, A.M. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8(5), 393-406.
55. Nakajima, T.; Maekita, T.; Oda, I.; Gotoda, T.; Yamamoto, S.; Umemura, S.; Ichinose, M.; Sugimura, T.; Ushijima, T.; Saito, D. Higher methylation levels in gastricmucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006, 15(11), 2317-2321. (Pubitemid 44877064)
56. Maier, S.; Nimmrich, I.; Koenig, T.; Eppenberger-Castori, S.; Bohlmann, I.; Paradiso, A.; Spyratos, F.; Thomssen, C.; Mueller, V.; Nahrig, J.; Schittulli, F.; Kates, R.; Lesche, R.; Schwope, I.; Kluth, A.; Marx, A.; Martens, J.W.; Foekens, J.A.; Schmitt, M.; Harbeck, N. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients - technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer 2007, 43(11), 1679-1686. (Pubitemid 47042374)
57. Ohba, T.; Ishino, M.; Aoto, H.; Sasaki, T. Dot far-western blot analysis of relative binding affinities of the Src homology 3 domains of Efs and its related proteins. Anal Biochem 1998, 262(2), 185-192. (Pubitemid 28452777)
58. Yue, C.M.; Deng, D.J.; Bi, M.X.; Guo, L.P.; Lu, S.H. Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol 2003, 9(6), 1174-1178.